Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 50
Summary
- Conditions
- Advanced Solid Tumors
- Pancreatic Cancer
- Solid Tumors
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02546531
- Collaborators
- The Foundation for Barnes-Jewish Hospital
- Merck Sharp & Dohme Corp.
- Verastem, Inc.
- Investigators
- Principal Investigator: Kian-Huat Lim, M.D., Ph.D. Washington University School of Medicine